To read the full article, click here.

Starpharma today released its annual report and financial results for the year ended 30 June 2019.

Starpharma today announced that promising efficacy signals have been observed in its ongoing clinical trials for both DEP^® cabazitaxel and DEP^® docetaxel.  

Starpharma today announced that it has received the first regulatory approvals in South East Asia for VivaGel^® BV. Mundipharma will be rolling-out the product in Asia under the brand name BETADINE^TM BV Gel.

Starpharma today announced that it has received the necessary regulatory and ethics approvals and will  commence its phase 1/2 clinical trial for DEP^® irinotecan. The objectives of the trial are to evaluate the safety, tolerability and pharmacokinetics of DEP^® irinotecan to define a recommended phase 2 dose (RP2D), and to determine anti-tumour efficacy of the product in select tumour types. DEP^® irinotecan is the third DEP^® product to enter the clinic from Starpharma’s internal portfolio with a fourth, partnered DEP^® candidate, AZD0466, also set to enter the clinic later this year.

Starpharma CEO Dr Jackie Fairley speaks with Alan Kohler for online investor publication The Constant Investor, where she discussed the launch of VivaGel BV in Australia and Europe as well as the company’s latest developments in its DEP^® portfolio. To listen to the full interview, click here.

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 30 June 2019.

In this issue: 

>> VivaGel^® BV launched in Europe & Australia; US regulatory progress

>> VivaGel condom launched in Japan by Okamoto

>> DEP^® docetaxel & DEP^® cabazitaxel clinical trial update; DEP^® irinotecan trial start & new data

>> Starpharma signs second commercial oncology agreement with AstraZeneca

>> AstraZeneca highlights AZD0466 at 2019 ASCO meeting & upcoming US FDA IND 

>> Patent published for AstraZeneca Bcl2/xL DEP conjugates

>> DEP^® radiotherapeutics

>> Outlook, recent news & events

Starpharma today announced that VivaGel^® BV has been launched in Europe under the brand name Betadine BV^TM. The product has been launched in several countries in Europe, including Germany, with further roll-out in additional European countries during the year.

Starpharma has been invited to present at the Macquarie Emerging Leaders Corporate Forum in Melbourne. The Macquarie Emerging Leaders Corporate Forum provides Starpharma with an opportunity to present to more than 100 investors from Melbourne and Sydney.